ZaBeCor Moves siRNA-Based Asthma Drug into Phase II
September 17, 2009
ZaBeCor Moves siRNA-Based Asthma Drug into Phase II
The decision was made after a phase I showed patients experienced no serious adverse effects, while 75 percent of patients reported an “improved ability to breathe freely or reduced use of their rescue inhaler.”
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant
March 4, 2010 / Gene Silencing News - NIH Awards $1.3M in siRNA Delivery-Related Grants Last Month
April 12, 2012 / Gene Silencing News - New Products: Takara Bio Europe's Xfect siRNA Transfection Reagent; Exiqon's miRcury LNA microRNA Array
March 29, 2012 / Gene Silencing News - Q&A: MIT's Paula Hammond on siRNA Delivery Via All-RNA Microsponges
March 1, 2012 / Gene Silencing News - New Products: Qiagen's FlexiPlate siRNA Libraries
January 26, 2012 / Gene Silencing News